JP2006525345A - 薬物耐性であると通常みなされている生物に対して抗菌薬物に効力を与える処方物 - Google Patents

薬物耐性であると通常みなされている生物に対して抗菌薬物に効力を与える処方物 Download PDF

Info

Publication number
JP2006525345A
JP2006525345A JP2006513447A JP2006513447A JP2006525345A JP 2006525345 A JP2006525345 A JP 2006525345A JP 2006513447 A JP2006513447 A JP 2006513447A JP 2006513447 A JP2006513447 A JP 2006513447A JP 2006525345 A JP2006525345 A JP 2006525345A
Authority
JP
Japan
Prior art keywords
composition
surfactant
acid
particles
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006513447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525345A5 (https=
Inventor
バーレット イー． ラビノウ，
ランディー ホワイト，
チョン−ソン サン，
ジョセフ チュン タック ウォン，
ジェームス イー． キップ，
マーク ジェイ． ドティ，
クリスティーン エル． レベック，
パブロス パパドポウロス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Publication of JP2006525345A publication Critical patent/JP2006525345A/ja
Publication of JP2006525345A5 publication Critical patent/JP2006525345A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2006513447A 2003-04-29 2004-04-29 薬物耐性であると通常みなされている生物に対して抗菌薬物に効力を与える処方物 Withdrawn JP2006525345A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46635403P 2003-04-29 2003-04-29
PCT/US2004/013268 WO2004096180A1 (en) 2003-04-29 2004-04-29 Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug

Publications (2)

Publication Number Publication Date
JP2006525345A true JP2006525345A (ja) 2006-11-09
JP2006525345A5 JP2006525345A5 (https=) 2007-06-21

Family

ID=33418369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006513447A Withdrawn JP2006525345A (ja) 2003-04-29 2004-04-29 薬物耐性であると通常みなされている生物に対して抗菌薬物に効力を与える処方物

Country Status (11)

Country Link
EP (1) EP1617818A1 (https=)
JP (1) JP2006525345A (https=)
KR (1) KR20060015553A (https=)
CN (1) CN1794975A (https=)
AU (1) AU2004234003A1 (https=)
BR (1) BRPI0409929A (https=)
CA (1) CA2523151A1 (https=)
MX (1) MXPA05011607A (https=)
NO (1) NO20055616L (https=)
WO (1) WO2004096180A1 (https=)
ZA (1) ZA200508467B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500542A (ja) * 2007-10-10 2011-01-06 アバンテイス・フアルマ・エス・アー 新規タキソイドに基づく組成物
JP2014502616A (ja) * 2010-12-30 2014-02-03 レスパブリカンスコエ ゴスダルストヴェンノエ プレドプリヤティエ ”ナウチニイェ センター プロティヴォインフェクチオニー プレパラトフ” コミテタ プロミツェレンノスティ ミニステルストヴァ インダストリー アイ ノヴィー テクノロジー レスパブリキ カザフスタン 細菌由来の感染症を治療する抗細菌剤

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100858508B1 (ko) 2005-12-23 2008-09-12 주식회사 삼양사 아졸계 항진균제를 포함하는 조성물 및 그의 제조방법
SG170047A1 (en) * 2006-05-30 2011-04-29 Elan Pharma Int Ltd Nanoparticulate posaconazole formulations
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
CN102085176A (zh) * 2010-12-31 2011-06-08 江苏中丹制药有限公司 一种纳米级伊曲康唑外用制剂、其制备方法及其用途
CN102106832A (zh) * 2011-02-12 2011-06-29 华中师范大学 酮康唑纳米混悬剂冻干粉及其制备方法
JP6962655B2 (ja) * 2015-07-07 2021-11-05 ライフラフト バイオサイエンシーズ，インコーポレイテッド 低ナトリウムポロキサマー１８８製剤および使用方法
CN111658601A (zh) * 2020-06-12 2020-09-15 浙江普利药业有限公司 伏立康唑外用制剂及其制备方法
IT202000030443A1 (it) * 2020-12-10 2022-06-10 Zambon Spa Polvere inalabile comprendente voriconazolo in forma cristallina
WO2025023975A1 (en) * 2023-07-27 2025-01-30 Bard Peripheral Vascular, Inc. Methods for the preparation of phospholipid bilayer carriers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100635456B1 (ko) * 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
AU7984200A (en) * 1999-09-21 2001-04-24 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
NZ526608A (en) * 2000-12-22 2006-06-30 Baxter Int Method for preparing submicron particle suspensions
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500542A (ja) * 2007-10-10 2011-01-06 アバンテイス・フアルマ・エス・アー 新規タキソイドに基づく組成物
JP2014502616A (ja) * 2010-12-30 2014-02-03 レスパブリカンスコエ ゴスダルストヴェンノエ プレドプリヤティエ ”ナウチニイェ センター プロティヴォインフェクチオニー プレパラトフ” コミテタ プロミツェレンノスティ ミニステルストヴァ インダストリー アイ ノヴィー テクノロジー レスパブリキ カザフスタン 細菌由来の感染症を治療する抗細菌剤

Also Published As

Publication number Publication date
NO20055616L (no) 2006-01-25
KR20060015553A (ko) 2006-02-17
NO20055616D0 (no) 2005-11-28
AU2004234003A1 (en) 2004-11-11
CA2523151A1 (en) 2004-11-11
ZA200508467B (en) 2006-09-27
MXPA05011607A (es) 2005-12-15
CN1794975A (zh) 2006-06-28
BRPI0409929A (pt) 2006-04-25
EP1617818A1 (en) 2006-01-25
WO2004096180A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
US8263131B2 (en) Method for treating infectious organisms normally considered to be resistant to an antimicrobial drug
ES2340261T3 (es) Composicion estable que comprende particulas en una matriz acuosa congelada.
US20030072807A1 (en) Solid particulate antifungal compositions for pharmaceutical use
US20050244503A1 (en) Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents
JP2002509876A (ja) 水不溶性物質のマイクロ粒子を製造するための組成物及び方法
EP1713443A2 (en) Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
Elsebay et al. Nanosuspension: a formulation technology for tackling the poor aqueous solubility and bioavailability of poorly soluble drugs
JP2006525345A (ja) 薬物耐性であると通常みなされている生物に対して抗菌薬物に効力を与える処方物
MX2007015183A (es) Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
HK1088536A (en) Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
HK40102079A (zh) 一种速溶型纳米粒子组合物及其制备方法
HK1087919A (en) Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents
MXPA06008533A (en) Nanosuspensions of anti-retroviral agents for increased central nervous system delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070427

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090210